By Maggie Fick and Michael Erman SAN FRANCISCO, Jan 26 (Reuters) - Artificial intelligence has yet to deliver on the most ...

The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development ...

A new analysis of drug trials used to approve medicines in the United States shows how far modern medicine still has to go to ...

The pharmaceutical industry is experiencing its own “DeepSeek moment,” according to science writer Hiya Jain. Just as the upstart AI breakthrough caught Silicon Valley off-guard, China is emerging as ...

FDA proposes framework clinical trial designs to guide Bayesian methods, improving efficiency in drug development for rare and pediatric conditions.

The Centre amends drug rules, streamlining approval processes and reducing timelines to enhance clinical research and ...

The Food and Drug Administration (FDA) has issued a new guidance document entitled “Enhancing Participation in Clinical Trials – Eligibility Criteria, Enrollment Practices, and Trial Decision.” The ...

The FDA’s new draft guidance on Bayesian methodology signals a shift toward more flexible, data-driven clinical trial designs, enabling sponsors to use prior data and adaptive approaches to improve ...

The Union Ministry of Health and Family Welfare has taken a series of measures including simplification of regulatory processes and reduction of drug approval timelines to facilitate and speed up the ...

The Centre has notified key amendments to the New Drugs and Clinical Trials (NDCT) Rules, 2019, in line with the directions ...

Under earlier rules, drugmakers had to get a test licence from CDSCO to manufacture small quantities of drugs for research, ...

A new drug targets the nervous system.